Rwanda is among the countries interested in Lenacapavir, a newly approved, long-acting preventive injection, though its cost is seemingly out of reach for many developing countries.Manufactured by ...

A permanent halt in funding from the biggest contributor to the HIV/AIDS effort could set back decades of progress and put millions of lives at risk, despite efforts by many low- and middle-income ...

Conference on HIV Science (IAS 2025) concluded in Kigali after five dynamic days (July 13-17), delegates left with a mix of hope and concern--buoyed by scientific breakthroughs but unsettled by a ...

MELODY CHIRONDA | The Joint United Nations Programme on HIV/AIDS (UNAIDS) has warned that the global AIDS response is in ...

WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

For more than two decades, the global community has united to fight the HIV pandemic, achieving remarkable progress. New HIV transmissions and AIDS-related deaths have dropped significantly, and ...

Coalition of Women Living with HIV and Aids (Cowlha) says an initiative they introduced to promote adherence to anti-retroviral treatment (ART) is encouraging people living with HIV not to default. In ...

Six months after President Donald Trump's foreign aid cuts, millions have lost access to HIV prevention medication.

A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Experts, such as Lloyd Mulenga, M.Sc., M.B., Ch.B., Ph.D., discuss long-acting injectable HIV PrEP's potential in Zambia, ...